Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A brain health bootcamp for seniors: could group classes ward off dementia?

NCT ID NCT05529706

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests a 12-week group program designed to help adults aged 65 and older address modifiable risk factors for dementia, such as high blood pressure and cognitive decline. Participants meet weekly for an hour to learn about brain health and practice evidence-based lifestyle changes. The study aims to see if the program is acceptable, feasible, and shows early promise before moving to a larger trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a 12-week group-based brain health program covering dementia risk factors and behavior change
What this could lead to
If successful, this program could offer a scalable, community-based approach to reduce dementia risk in older adults.
What could go wrong
This is a small early-stage study focused on feasibility, not proof of effectiveness. Results may not translate to larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

86 people

The number who actually took part.

Started

Apr 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who are 65 years of age or older. 2. Participants who meet criteria for one or more ADRD dementia risk factors 1. Family history of Alzheimer's dementia (1st degree relative) 2. Genetic marker (APOE4++) 3. Subjective or objective cognitive decline (neuropsychological testing; or self-reported "yes" to the following question: "In the past two years, have you experienced a decline in your memory or thinking?" 4. Poorly controlled hypertension or diabetes 5. Physical inactivity \<150min/week per Surgeon General guidelines 6. Social isolation, in which participant rarely or never gets social and emotional support when needed 3. Participants who are fluent English or Spanish speakers, per self-report, to ensure reasonable neuropsychological results on key assessments. 4. Participants have access to an internet accessible device (eg. laptop, desktop computer, tablet or smartphone) 5. Participants are able to attend all 12 classes (once a week for 12 weeks) and make up missed classes, as needed 6. Participants are able to travel to/from YMCA location, if they choose to be a part of the in-person group Exclusion Criteria: 1. Inability to provide informed consent 2. Cognitive Abilities Screening Instrument - Short (CASI-Short) scores ≤ 25 (suggestive of cognitive impairment) 3. Participants with untreated psychiatric conditions, including substance abuse/dependence disorders. 4. Participants enrolled in a concurrent clinical trial involving an investigational pharmaceutical, nutraceutical, medical device, or behavioral treatment that could affect the outcome of this study. However, participation in standard treatments (e.g., occupational therapy) or use of prescribed medications (e.g., anti-depressants) is allowable. 5. Participants presently attending classes or courses like this program that is focused on dementia risk and behavior management.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • YMCA of San Francisco

    San Francisco, California, 94105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.